The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines, among others. At the same time, companies like Celldex ...

That acquisition included Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the U.S. and the EU, along with a promising advanced and early-stage immunology pipeline.

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K. The acquisition brings an early-stage combination vaccine ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

It also includes Ayvakit/Ayvakyt (avapritinib), a treatment for rare immunological diseases that has received approval in both the US and the European Union. The acquisition also covers elenestinib, a ...

In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologists which is expected to enhance Sanofi’s ability to advance its growing ...

Sanofi, an R&D driven, AI-powered biopharma company, announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its ...

Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), which is characterized by the accumulation and activation of aberrant mast cells in bone ...